TORONTO, Dec. 20, 2012 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") is pleased to announce that under a Letter
of Intent concluded on December 19th, 2012, Biosign and West Champlain
Healthy Community Corporation("WCHCC") have agreed to jointly launch
several initiatives in 2013. WCHCC & Biosign will conduct a consumer
marketability and user experience study for the Pulsewave™ Personal
Health Monitor, a new product bundle from Biosign that will include a
tablet PC, a Pulsewave™ PAD device and rich content applications that
enhance health & wellness. If the trial is successful, WCHCC will then
make Biosign Pulsewave™ consumer products available to their clients at
a time-limited promotional price to be agreed by the parties. In
addition, Biosign will conduct a public user-experience trial for the
new Biosign Healthanywhere™ Kiosk on the premises of WCHCC. During this
trial, one or more models of the Kiosk will be installed and WCHCC
clients who use the Kiosk (with guidance from a WCHCC staff member)
will be asked to record their responses via a survey. WCHCC then
intends to install one or more production-model Biosign Kiosks for the
continued use of staff and clients. Lastly, during 2013 WCHCC has
agreed to work with Biosign to complete one or more clinical validation
trials for new products that are currently being prepared for
regulatory approval, including a new Average Breathing Rate measurement
and the previously announced screening tool for Arrhythmias.
MANAGEMENT COMMENTS:
Biosign's CEO Mr. Robert Kaul stated: "We are very pleased to join
forces with West Champlain Healthy Community Corporation. We fully
support their mission, which is to enhance the health status of West
Champlain residents, providing the best available healthcare technology
to the people of the Ottawa Valley. Our goal is to provide WCHCC with a
suite of products that meets the needs of their clients."
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, computer
enabled health information products. Key applications include the
noninvasive monitoring of vital signs including blood pressure, pulse
rate and breathing rate, enhanced with web services. The Company's
Pulsewave™ medical device technology powers data collection for
clinical decision support, self-care, wellness and disease management,
while it's Healthanywhere™ software suite offers industry-leading
remote patient monitoring solutions. For more information on Biosign,
please visit www.biosign.com
About West Champlain Healthy Community Corporation.
WCHCC is a non-profit charitable organization based in Pembroke ON that
owns and operates the Ottawa Valley Health Center on the grounds of the
Pembroke Regional Hospital. The Health Center combines a full primary
care medical practice with a number of important health and wellness
programs including chronic disease clinics, dietary education services
and even a yoga studio.
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.